Table 3.

Performances of CA125, LAMC2 in diagnosis of CA19.9-negative PDAC patients

Training setValidation set
AUC (95% CI)PAUC (95% CI)P
Benign vs. all PDAC
 CA19.90.59 (0.46–0.72)0.20.54 (0.41–0.66)0.5
 CA1250.73 (0.62–0.84)0.00030.78 (0.67–0.88)<0.0001
 LAMC20.76 (0.65–0.86)<0.00010.64 (0.53–0.76)0.02
 CA125 + LAMC20.81 (0.71–0.90)<0.00010.76 (0.66–0.86)<0.0001
CP vs. early-stage PDAC
 CA19.90.53 (0.37–0.69)0.70.52 (0.35–0.70)0.8
 CA1250.72 (0.58–0.86)0.0070.77 (0.64–0.90)0.002
 LAMC20.79 (0.67–0.91)0.00020.62 (0.44–0.79)0.2
 CA125 + LAMC20.84 (0.73–0.95)<0.00010.73 (0.57–0.89)0.01

P values are calculated by the Wilcoxon test in the comparison between benign and cancer groups.